Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C2B | O00750 | 7/20 | 0.49 |
| ▸ | PIK3R2 | O00459 | 11/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.45 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19991587 | 0.89 | PIK3R2 (0.51) | PIK3R2PIK3CBPIK3CDPIK3R1PIK3CA | |
| SCHEMBL20009346 | 0.89 | PIK3C2B (0.58) | PIK3C2BPIK3R2PIK3CBPIK3CDPIK3R1 | |
| SCHEMBL19989103 | 0.86 | PIK3R2 (0.62) | PIK3R2PIK3CBPIK3CDPIK3R1PIK3CA | |
| SCHEMBL19988910 | 0.86 | PIK3R2 (0.65) | PIK3R2PIK3CBPIK3CDPIK3R1PIK3CA | |
| SCHEMBL19991576 | 0.83 | PIK3C2B (0.57) | PIK3C2BPIK3R2 | |
| SCHEMBL19989326 | 0.82 | PIK3R2 (0.64) | PIK3C2BPIK3R2PIK3CBPIK3CDPIK3R1 | |
| SCHEMBL19989183 | 0.80 | PIK3R2 (0.64) | PIK3R2PIK3CBPIK3CDPIK3R1PIK3CA | |
| SCHEMBL19988883 | 0.80 | PIK3R2 (0.62) | PIK3R2 | |
| SCHEMBL20009345 | 0.79 | PIK3C2B (0.51) | PIK3C2BPIK3R2PIK3CBPOLB | |
| SCHEMBL19989252 | 0.79 | PIK3R2 (0.64) | PIK3R2PIK3CBPIK3CDPIK3R1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10479770-B2 | Phosphatidylinositol 3-kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2019-11-19 | — | — | US | disclosed |
| US-20180086719-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20180086719-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2018-03-29 | — | — | US | disclosed |
| WO-2018057805-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086719-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3CA, AKT3, PI4KA | PIK3C2B 15/4885PIK3R2 30/4885PIK3CB 6/4885 |
| US-10479770-B2 | Phosphatidylinositol 3-kinase inhibitors | PIK3CA, AKT3, PI4KA | PIK3C2B 15/4885PIK3R2 30/4885PIK3CB 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.